About: Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France
Source	Medline; PMC
abstract	Linezolid is one of the most effective drugs for treating multidrug-resistant tuberculosis (MDR TB), but adverse effects remain problematic. We evaluated 57 MDR TB patients who had received >1 dose of linezolid during 2011–2016. Overall, patients received 600 mg/day of linezolid for a median of 13 months. In 33 (58%) patients, neurologic or ophthalmologic signs developed, and 18 (32%) had confirmed peripheral neuropathy, which for 78% was irreversible at 12 months after the end of TB treatment despite linezolid withdrawal. Among the 19 patients who underwent ophthalmologic evaluation, 14 patients had optic neuropathy that fully reversed for 2. A total of 16 (33%) of 49 patients had a linezolid trough concentration >2 mg/L, and among these, 14 (88%) experienced adverse effects. No significant association was found between trough concentration and neurologic toxicity. These findings suggest the need to closely monitor patients for neurologic signs and discuss optimal duration of linezolid treatment.
has issue date	2020-08-01(xsd:dateTime)
bibo:doi	10.3201/eid2608.191499
bibo:pmid	32687026
has license	no-cc
sha1sum (hex)	f3f307dc37d36435314d291730db7b0c81c2d15d
schema:url	https://doi.org/10.3201/eid2608.191499
resource representing a document's title	Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France
has PubMed Central identifier	PMC7392460
has PubMed identifier	32687026
schema:publication	Emerg Infect Dis
resource representing a document's body	covid:f3f307dc37d36435314d291730db7b0c81c2d15d#body_text
is schema:about of	named entity 'linezolid' named entity 'ethambutol' named entity 'neurologic' named entity 'peripheral neuropathy' named entity 'analgesia' named entity 'neurologic' named entity 'electromyography' named entity 'linezolid' named entity 'linezolid' named entity 'signs/symptoms' named entity 'neuropathy' named entity 'tendon reflexes' named entity 'Ophthalmologic' named entity 'lobectomy' named entity 'WHO' named entity 'linezolid' named entity 'color vision' named entity 'laryngeal' named entity 'Linezolid' named entity 'peripheral neuropathy' named entity 'linezolid' named entity 'clinical examination' named entity 'TB treatment' named entity 'neurologic' named entity 'signs/symptoms' named entity 'neurotoxic' named entity 'TB treatment' named entity 'mass spectrometry' named entity 'neurologic' named entity 'follow-up' named entity 'adverse effects' named entity 'ethambutol' named entity 'cranial nerve' named entity 'toxicity' named entity 'TB treatment' named entity 'neurologic' named entity 'long-term' named entity 'ophthalmologic' named entity 'scotoma' named entity 'neuropathy' named entity 'optic neuropathies' named entity 'neurologic' named entity 'optical coherence tomography' named entity 'TB treatment' named entity 'rifampicin' named entity 'ethionamide' named entity 'multidrug-resistant tuberculosis' named entity 'intravenous drugs' named entity 'MDR TB' named entity 'impaired vision' named entity 'optic neuropathy' named entity 'neuropathy' named entity 'Pitié-Salpêtrière Hospital' named entity 'clinical examination' named entity 'linezolid' named entity 'follow-up' named entity 'toxicity' named entity 'European Medicines Agency' named entity 'visual impairment' named entity 'visual acuity' named entity 'linezolid' named entity 'cycloserine' named entity 'opioids' named entity 'brainstem' named entity 'adverse effects' named entity 'linezolid' named entity 'opioids' named entity 'visual acuity' named entity 'linezolid' named entity 'neurologic' named entity 'MDR TB' named entity 'alcohol dependency' named entity 'linezolid' named entity 'high-performance liquid chromatography' named entity 'diabetes' named entity 'MDR TB' named entity 'adverse effects' named entity 'etiologies' named entity 'sensory neuropathy' named entity 'neurologic' named entity '1, 2' named entity 'signs/symptoms'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software